Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Felix Yang

EP · NYU Langone

View

Dr. Gregory Marcus

EP · UCSF

View

Dr. Miguel Leal

EP · Emory University Hospital

View

Dr. Chirag Barbhaiya

EP · NYU

View

Dr. William Sauer

EP · BWH

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Brahmajee Nallamothu

Interventional Cardiology · UMHS

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Antithrombotic Therapy after Ablation for Atrial Fibrillation

    May 7, 2026DOI: 10.1056/nejmc2602513CorrespondenceNEJM

    Summary

    To the Editor: In the recent OCEAN (Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation) trial involving patients who had undergone successful catheter ablation for atrial fibrillation, Verma et al. (Jan. 22 issue) report that the incidence of the primary trial outcome (a composite of stroke, systemic embolism, or new covert embolic stroke) was not significantly lower among those treated with reduced-dose rivaroxaban (15 mg per day) than among those treated with aspirin. Generalizing the results of this trial to the patient population with atrial fibrillation may be challenging because the mean CHA2DS2-VASc score (scores range from . . .
    LPDr. Leon Ptaszek

    Dr. Leon Ptaszek

    Cardiology · Cardiac Electrophysiology
    Massachusetts General Hospital
    leon